STOCKHOLM, Aug. 31, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the company has received regulatory approval from the British Medicines & Healthcare products Regulatory Agency (MHRA) for its upcoming phase 1/2a combination study with the company's leading...
from PR Newswire: https://ift.tt/3kKjKY2
No comments:
Post a Comment